TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06333808
Drug: Lenacapavir
Normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT06524375
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax tablets will be administered as per the schedule specified in the arm.
Study: NCT06524375
Drug: cBTKi Monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available cBTKi (ibrutinib or acalabrutinib, or zanubrutinib) will be administered in accordance with its prescribing label.
Study: NCT06538272
Drug: ONO-2910
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-2910 Tablet will be orally administered once daily.
Study: NCT04817241
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04817241
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04817241
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04676516
Drug: GSK3326595
Normalized name: Protein arginine methyltransferase 5 inhibitor gsk3326595
DrugBank: Pemrametostat (DB19170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
Study: NCT05007782
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Intravenously
Study: NCT04747613
Drug: Iptacopan
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral
Study: NCT04396873
Drug: 11C-MC1
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected IV followed by PET scanning
Study: NCT04396873
Drug: 11C-PS13
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected IV followed by PET scanning
Study: NCT04396873
Drug: 18f-florbetaben
Normalized name: florbetaben (18F)
DrugBank: Florbetaben F-18 (DB09148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected IV followed by PET scanning
Study: NCT04752215
Drug: BI 765049
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 765049
Study: NCT06709274
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80mg daily, for EGFR-positive patients
Study: NCT06709274
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600mg BID, for ALK-rearranged patients
Study: NCT06709274
Drug: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
Normalized name: toripalimab Injection
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 240mg + Platinum-based chemotherapy (Q3W for 4 cycles), followed by Toripalimab maintenance therapy (240mg Q3W for one year), for EGFR/ALK wildtype patients
Study: NCT04752215
Drug: ezabenlimab
Normalized name: Ezabenlimab
DrugBank: Ezabenlimab (DB17483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezabenlimab
Study: NCT04551040
Drug: Terazosin
Normalized name: Terazosin
DrugBank: Terazosin (DB01162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terazosin 1 mg oral capsule
Study: NCT06511063
Drug: tenofovir disoproxil/emtricitabine
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take Truvada (TDF/FTC, tenofovir disoproxil/emtricitabine) for 90 days.
Study: NCT06511063
Drug: Selzentry
Normalized name: Selzentry
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take Selzentry for 90 days.
Study: NCT06066346
Drug: Talquetamab
Normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talquetamab will be administered SC until disease progression
Study: NCT06197295
Drug: Solifenacin with vaginal estrogen cream
Normalized name: estrogens, conjugated (USP) Vaginal Cream [Premarin]
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg
Study: NCT04933669
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib neoadjuvant therapy
Study: NCT05780723
Drug: Control group: Mesalazine enema treatment
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine enema, 4g/tube, 1 tube each time, enema before bed, once a night, a total of 8 weeks of continuous treatment.
Study: NCT06222034
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Film-coated mini-tablets administered orally once daily
Study: NCT06222034
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Commercially developed film-coated tablet administered orally once daily
Study: NCT06044025
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will start with metformin 500 mg by mouth (po) two times daily (bid) with meals for 14 days. Metformin titration will then increase to 850 milligram (mg) po bid for 14 days before increasing titration to a desired dosage of 1,000 mg po bid. For those subjects currently taking Metformin, they will continue current dose (if 1,000 mg po bid) or titrate dose as just described until maximum dose is achieved.
Study: NCT06044025
Drug: Turmeric
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will start with 1,500 mg turmeric po daily with meals. The dose can be temporarily reduced to 1,000 mg po daily for those who report GI discomfort. If GI discomfort has resolved within one month of the dose reduction, subjects will resume 1,500 mg po daily. If GI discomfort has not resolved or resumes at increased dose, the subject may be instructed to stop taking the study treatment and removed from the study.
Study: NCT05378100
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of ketamine 0.5 mg/kg over 40 minutes
Study: NCT05378100
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion of midazolam 0.05 mg/kg over 40 minutes
Study: NCT06464991
Drug: Equecabtagene Autoleucel Injection
Normalized name: Obecabtagene autoleucel
DrugBank: Equecabtagene autoleucel (DB19016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.
Study: NCT06464991
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dosage form: Injection dose level:16mg/kg frequency: 28days/cycle for DPd regimen~* Cycle1-2：D1, D8, D15, D22；~* Cycle3-6：D1, D15；~* above Cycle7：D1
Study: NCT06464991
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.
Study: NCT06464991
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11； above cycle 9: D1, D8.
Study: NCT06464991
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23； for PVd: Cycle1-8：D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.
Study: NCT05469178
Drug: Bemcentinib
Normalized name: Bemcentinib
DrugBank: Bemcentinib (DB12411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemcentinib capsules will be administered orally.
Study: NCT05469178
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered as an intravenous (IV) infusion as part of CIT every 3 weeks.
Study: NCT05469178
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.
Study: NCT05469178
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks up to 4 cycles. Each cycle = 21 days.
Study: NCT06179485
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
Study: NCT06179485
Drug: Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
Study: NCT06336798
Drug: Pioglitazone 30mg
Normalized name: GLIMEPIRIDE 2MG/PIOGLITAZONE 30MG TAB
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants will take Pioglitazone 30 mg PO daily
Study: NCT05970172
Drug: Roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Oral
Study: NCT05912816
Drug: RC48 Combined With Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this trial, RC48 was scheduled to be administered at a dose of 2.0 mg/kg every 3 weeks, with the first dose on day 1 of the first cycle.~Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle. The drug is diluted with normal saline and administered by intravenous drip for one hour.
Study: NCT04927000
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: in tofacitinib treatment group，we added tofacitinib 5mg/BID in the basic treatment in all subjects.
Study: NCT05168280
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively.
Study: NCT04803994
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg atezolizumab intravenously Q3W (max 32 cycles, up to 24 months)
Study: NCT04803994
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg intravenously Q3W (max 32 cycles, up to 24 months)
Study: NCT05986682
Drug: Blenrep
Normalized name: Blenrep
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab Mafodotin - blmf (BLENREP) given for the treatment of relapsed and/or refractory multiple myeloma.
Study: NCT05418088
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06310954
Drug: Common diet combined with conventional pharmacotherapy
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this arm will receive a standard diet without any ketogenic restrictions, alongside conventional antiepileptic drugs. This comparator aims to assess the standard care's efficacy against the experimental intervention, focusing on seizure control, and inflammatory markers, and identifying patient characteristics associated with treatment responsiveness.We know that drug information for registering clinical information is necessary, but our research design is to add ketogenic diets as a supplementary treatment plan when traditional drug treatment is ineffective. Therefore, in terms of specific drug selection, this is not absolutely the same. Depending on individual differences, the choice of drugs will also vary. Control the number of episodes, time, etc., and everyone uses different drugs. Therefore, we cannot decide on a single drug for comparison like traditional content.
Study: NCT05266274
Drug: CD47 monoclonal antibody
Normalized name: Anti-cd47 monoclonal antibody hu5f9-g4
DrugBank: Magrolimab (DB16225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation
Study: NCT05801354
Drug: Turmeric Gel
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric gel will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
Study: NCT05801354
Drug: Formocresol
Normalized name: Formocresol
DrugBank: Cresol (DB11143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
Study: NCT05540977
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil 5mg QN
Study: NCT05105022
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous induction of general anesthesia in infants 3 months or less.
Study: NCT05307731
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM
Study: NCT06149286
Drug: Odronextamab
Normalized name: Odronextamab
DrugBank: Odronextamab (DB16684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous (IV) infusion
Study: NCT06149286
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally (PO)
Study: NCT06149286
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by IV infusion, or subcutaneously (SC)
Study: NCT06091956
Drug: Deucravacitinib
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 milligram (mg) orally administrated, twice daily
Study: NCT06521554
Drug: NVL-330
Normalized name: NVL-655
DrugBank: NVL-655 (DB18682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet of NVL-330
Study: NCT03950037
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole; 15 mg/k/d divided in two doses (morning and evening), for 30 days, with a ceiling in 1200 mg/d.
Study: NCT04132882
Drug: Sodium Thiosulfate (STS)
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06092645
Drug: surufatinib plus cadonilimab
Normalized name: Cadonilimab
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib: 250mg , po,qd, d1-d21, every 3 weeks for a treatment cycle. Cadonilimab: 10mg/kg, iv, d1, every 3 weeks for a treatment cycle
Study: NCT06019130
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases
Study: NCT06019130
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin during induction chemotherapy and during radiochemotherapy in all groups
Study: NCT06019130
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluoruracil during induction chemotherapy in all groups except of adults \> 25 years with metastatic disease at diagnosis
Study: NCT06019130
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine during induction chemotherapy in patients \> 25 years with metastatic disease at diagnosis
Study: NCT06019130
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In patients \< 26 years after end of radiochemotherapy for 6 months
Study: NCT06270030
Drug: LNZ101 (Aceclidine /Brimonidine) ophthalmic solution
Normalized name: brimonidine Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
Study: NCT06270030
Drug: LNZ100 (Aceclidine) ophthalmic solution
Normalized name: Aceclidine
DrugBank: Aceclidine (DB13262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
Study: NCT06186440
Drug: Cisplatin Plus Temozolomide
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin Plus Temozolomide . Cisplatin 20mg/mCisplatin days 1-5
Study: NCT06186440
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide
Study: NCT06135493
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using losartan to prevent paclitaxel-induced peripheral neuropathy
Study: NCT06547866
Drug: zanubrutinib + BGB-11417
Normalized name: Zanubrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The investigational medicinal products (IMP) are Zanubrutinib (BGB- 3111) and BGB-11417.Treatment will be administered for a total of twenty 28 day cycles:~Cycle 1 with zanubrutinib only~Cycle 2 with zanubrutinib plus BGB-11417 ramp-up cycle 2, day 1 : 10mg cycle 2, day 2 : 20 mg cycle 2, day 3 : 40mg cycle 2, day 4-7 : 80md daily cycle 2, day 8 and beyond : 160 mg daily~Cycles 3-20 with zanubrutinib plus BGB-11417 full dose
Study: NCT05090566
Drug: Elranatamab + Nirogacestat
Normalized name: elranatamab
DrugBank: Nirogacestat (DB12005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA-CD3 bispecific antibody + gamma secretase inhibitor
Study: NCT05090566
Drug: Elranatamab + lenalidomide + dexamethasone
Normalized name: elranatamab
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BCMA-CD3 bispecific antibody + immunomodulatory
Study: NCT06171685
Drug: Teclistamab Monotherapy
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care
Study: NCT06171685
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational doses compared to SOC
Study: NCT05926882
Drug: Apremilast 30mg
Normalized name: APREMILAST 30MG TAB
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be given Oral Apremilast 30 mg twice daily after 05 days titration dose.
Study: NCT05282277
Drug: Micronized Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
Study: NCT05282277
Drug: Raclopride C11
Normalized name: Choline C11
DrugBank: Raclopride (DB12518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.
Study: NCT06099639
Drug: HER3-DXd
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.6 mg/kg Q3W \[on Day 1 of each 21-day cycle\]) infused IV over approximately 90 minutes
Study: NCT05089019
Drug: Selpercatinib
Normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT06232109
Drug: Fluvoxamine
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT06232109
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT06232109
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT06232109
Drug: ASN51
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT05463783
Drug: Biktarvy
Normalized name: Biktarvy
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: microRNA profiles of subjects on Biktarvy, will be compared with those who are on Symtuza, at various time points.
Study: NCT05463783
Drug: Symtuza
Normalized name: Symtuza
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: microRNA profiles of subjects on Symtuza, will be compared with those who are on Biktarvy, at various time points.